ClinicalTrials.gg

Program

SAR448851

A development code.

In Sanofi’s pipeline, TREM2 agonist. Its studies are mostly in Alzheimer Disease, led by Sanofi.

Furthest: phase 2, since Jun 30, 20261 company-led study, 1 open or runningNext primary completion: Jul 31, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 2since Jun 30, 2026Jun 30, 2026Jul 31, 2029phase 2 · NCT07688213
  • Named in Sanofi’s own pipeline as SAR448851, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2026First study: phase 2 study in Alzheimer DiseaseFirst studyNCT07688213 · 160 planned · United States, Australia, Canada and more

Ahead

  1. Jul 31, 2029Primary completion: phase 2 study in Alzheimer DiseaseNCT07688213

TargetBeta

“TREM2 agonist”the company's pipeline, read by Claude · source

Other programs on TREM2

ProgramCompanyFurthest phaseStudies
Anti-TREM2 Monoclonal Antibody EOS006215ruleiteos-belgium-saphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07688213Alzheimer Disease · United States, Australia, Canada and more2RecruitingJul 31, 2029160

How it is read

Names in the registry

  • “SAR448851”, 1 entry

Codes read as this program: SAR448851.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.